The policy is to support primary health care businesses to jointly develop the clinic market

On November 18th, the first pharmaceutical business and clinic alliance in China, Guangdong Good Medicine Chain Clinic Alliance, was established and the first general meeting of its members was held. Some analysts pointed out that the establishment of Guangdong good medicine chain clinic alliance, it is to see the national policy tilt to the grass-roots market, and the clinic market has not yet national, or even regional strong alliance appeared, and finally by the regional strong commercial companies to lead the formation of an alliance to integrate the resources of commercial companies, with the scale advantage to win market advantage.Pharma Business and Clinics" model
According to reporters understand, Guangdong Good Medicine Chain Clinic Alliance by Guangzhou Guoying Pharmaceutical Co., Ltd. and Guangdong Liangfang Pharmaceutical Co., Ltd. co-sponsored by 21 cities in Guangdong Province to develop a third terminal promotion-based pharmaceutical core business companies, with a number of county leading pharmaceutical companies jointly formed. The Alliance mainly serves primary medical institutions, including individual clinics, private hospitals, township hospitals, community service centers (stations), village health rooms (stations) and so on.
, the pharmaceutical business sector is one of the most active parts of the entire pharmaceutical industry chain. Previously, the pharmaceutical industry has appeared a number of commercial alliances for the hospital market, for the pharmacy market business alliances are not in the minority. However, the commercial alliance for the grass-roots clinic, which was once less "eye-catching", has yet to emerge.
Guangdong Good Medicine Chain Clinic Alliance will establish a network of 50 counties and 20,000 clinics covering 21 cities and cities in Guangdong Province, and establish a professional clinic operation team to provide professional and efficient services to clinics. To the alliance members, the establishment of the alliance agent product procurement and distribution system, including product general agent, centralized procurement, outsourcing service procurement, promotional supplies procurement. "The first executive director of Guangdong Good Medicine Chain Clinic Alliance and chairman of Guangdong Liangfang Pharmaceutical Co., Ltd. Said at the inaugural meeting.
Luo Zhiyong, general manager of Guangzhou Guoying Pharmaceutical Co., Ltd., pointed out that as a commercial company, service value-added is the most important, Guoying's customers are mainly hospitals, for the clinic does not have the ability to pay attention to, must rely on partners to form a business structure. With the rapid development of big health, and the policy environment of supporting graded diagnosis and treatment and multi-point practice of physicians, grass-roots clinics have ushered in a period of opportunity for development, and cooperation between different regional commercial companies will share the dividends of market expansion.business to jointly develop the clinic market
with the introduction of national health care reform policy, especially the implementation of the "two-vote system", is and is about to bring about great changes in the pharmaceutical industry chain. At present, there are 31 provinces, districts and cities in the country intensive introduction of drug procurement "two-vote system" implementation advice, most cities have clear implementation time or has begun to implement, "two-vote system" this year and next year will be a large area of the country. If the "two-vote system" is fully pushed out, the impact on the pharmaceutical industry will be that bargaining power will be improved and profits are expected to rise further as industry needs high insulation. "But this is only a data growth, increased tax burden, withdrawal pressure and other factors, will make the pharmaceutical industry have to change its business model, mergers and acquisitions of commercial companies, entrusted to CSO, the emergence of a new batch of industrial and commercial alliances, thereby conducive to the restructuring of the pattern, the overall benefit to industry." The
the "two-vote system" on commercial companies is subversive, as opposed to industrial companies. "As health care charges become more stringent, it will be more difficult to sell drugs at the first terminal in 2018. In particular, the policy of 'residual balance, reasonable overspend sharing' has been introduced in some places, further enhancing the enthusiasm of secondary bargaining in public hospitals. The price advantage of pharmacy terminals is weakening as public hospitals abolish drug charges and the state introduces graded treatment. And clinics and other third terminal market is a virgin is being developed, the market space is huge. Ko Huasong said.
in the procurement of pharmaceutical tenders, with the development of medical associations, the GPO procurement model may bring challenges to the bidding and procurement of provinces, and the bargaining power of medical institutions has never been greater. Some three-level hospitals lead the formation of a medical association, the formation of GPO procurement, will further depress drug prices, the formation of price advantage. And in the medical union, through the implementation of graded diagnosis and treatment, will further reduce the long prescription of chronic disease drugs to the grass-roots level, is conducive to pulling the grass-roots slow disease market.
On the one hand, the bargaining power of industrial enterprises is improved, on the other hand, the hospital's second bargaining enthusiasm is increased, in the upstream and downstream double squeeze, leaving the opportunity for commercial companies seems to be only the national policy of the grass-roots clinic market.
the first half of 2017, sales of seven major categories of pharmaceutical products totaled 989.4 billion yuan, up only 8.1% year-on-year, according to data released by the CFDA Southern Institute of Pharmaceutical Economics. Sales at all three terminals in 2017 were lower than expected, with hospital drug sales up just 7% year-on-year, the retail market growing by only 8% this year, and the primary care market growing by more than double digits to 11.6%, although lower than expected.
in the context of the continued decline in pharmaceutical business growth, how to grasp the existing market opportunities, testing the wisdom of pharmaceutical business enterprises. It remains to be seen whether the Guangdong Good Medicine Chain Clinic Alliance can achieve the desired results and achieve the desired goals. (Medical Economics)